SomaLogic's assets were acquired directly by Illumina, Inc., a leading global pioneer in DNA sequencing and array-based technologies. Standard BioTools completed the transaction, transferring the SomaScan assay services and related proprietary platforms to Illumina in exchange for an upfront cash payment supplemented by potential earnout milestones and commercial royalty agreements. This acquisition allowed Illumina to integrate advanced proteomics directly into its broader life sciences ecosystem, while Standard BioTools utilized the capital proceeds to strengthen its balance sheet and pursue other corporate growth initiatives.